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Abstract 
Background: Chronic HF with reduced ejection fraction (HFrEF) impairs health related quality 
of life (HRQL). Omecamtiv mecarbil, a novel activator of cardiac myosin, improves left 
ventricular systolic function and remodeling and reduces natriuretic peptides. We sought to 
evaluate the effect of omecamtiv mecarbil on symptoms and HRQL in patients with chronic 
HFrEF and elevated natriuretic peptides enrolled in the COSMIC-HF trial. 
Methods: Patients (n = 448) were randomized 1:1:1 to placebo, 25 mg of omecamtiv mecarbil 
twice daily (OM 25 mg), or to pharmacokinetically-guided dose titration (OM-PK) for 20 weeks. 
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was administered to assess HRQL at 
baseline, 16 weeks, and 20 weeks. The primary scores of interest were the Total Symptom Score 
(TSS), Physical Limitation Scale (PLS), and Clinical Summary Score (CSS).  
Results: Mean change in score from baseline to 20 weeks for the TSS was 5.0 (95%CI: 1.8-8.1) 
for placebo, 6.6(95%CI: 3.4-9.8) for OM 25 mg (p = 0.32 vs placebo), and 9.9 (95%CI: 6.7-13.0) 
for OM-PK (p = 0.03 vs placebo); for the PLS, it was 3.1 for placebo (95%CI: -0.3-6.6), 6.0 
(95%CI: 3.1-8.9)  for OM 25 mg (p=0.12), and 4.3 (95%CI: 0.7-7.9)   for OM-PK (p=0.42); for 
the CSS, it was 4.1 (95%CI: 1.4-6.9) for placebo, 6.3 (95%CI: 3.6-9.0)  for OM 25 mg (p=0.19), 
and 7.0 (95%CI: 4.1-10.0) for OM-PK (p=0.14). Differences between omecamtiv mecarbil and 
placebo were greater in patients who were more symptomatic at baseline.  
Conclusions: HRQL as measured by the TSS improved in patients with HFrEF assigned to 
omecamtiv mecarbil (OM-PK group) relative to placebo.  Ongoing trials are prospectively 
testing whether omecamtiv mecarbil improves symptoms and HRQL in HFrEF.  
Registration: clinicaltrials.gov; Unique Identifier: NCT01786512 
Key words: health outcomes; health-related quality of life; heart failure; quality of life 
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Nonstandard Abbreviations and Acronyms: 
HRQL = Health related quality of life 
GDMT = guideline directed medical therapy 
HFrEF = heart failure with reduced ejection fraction 
HF = heart failure 
PRO = patient reported outcome 
NYHA = New York Heart Association 
COSMIC-HF = Chronic Oral Study of Myosin Activation to Increase Contractility in Heart 
Failure 
LVEF = Left ventricular ejection fraction 
NT-proBNP = N-terminal pro B-type natriuretic peptide 
PK = pharmacokinetic 
KCCQ = Kansas City Cardiomyopathy Questionnaire 
TSS = total symptom score 
CSS = clinical summary score 
PLS = physical limitation score 
ACE = angiotensin converting enzyme 
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What Is New? 
• Omecamtiv mecarbil is a novel potential treatment for heart failure with reduced ejection
fraction (HFrEF) that works by directly targeting cardiac myosin to improve systolic
function.
• The Phase II COSMIC study demonstrated that omecamtiv mecarbil lowers natriuretic
peptide concentrations and induces favorable ventricular remodeling.
• The current report presents additional data from COSMIC on the effects of omecamtiv
mecarbil on health-related quality of life. Twenty weeks of treatment with omecamtiv
mecarbil resulted in numerically improved Kansas City Cardiomyopathy Questionnaire
(KCCQ) scores for the total symptom score, physical limitations score, and clinical
summary score compared to placebo, which was statistically significant for the total
symptom score.
What Are the Clinical Implications? 
• Impaired quality of life is a major problem for patients with HFrEF.
• If the magnitude of improvements in KCCQ scores reported here are confirmed in larger
studies such as the ongoing GALACTIC and METEORIC trials, omecamtiv mecarbil
would represent a significant advanced in medical therapy for HFrEF.
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Chronic heart failure is characterized by both a high risk of mortality and morbidity and by 
impairments in functional capacity and health related quality of life (HRQL). For patients with 
heart failure and reduced ejection fraction (HFrEF), the development of effective treatments 
(collectively called guideline directed medical therapy (GDMT) have resulted in progressive 
improvements in morbidity and mortality. Improvement in functional capacity and HRQL with 
these therapies has been less well documented. Many patients with chronic heart failure with 
reduced ejection fraction (HFrEF) continue to have a high symptom burden and poor HRQL 
despite current treatments.  Improving symptom burden and HRQL, especially in highly 
symptomatic patients, is therefore an important goal of treatment in heart failure1, as has been 
recently emphasized in regulatory guidance for drug development in heart failure2.  
Omecamtiv mecarbil is a selective cardiac myosin activator (“myotrope”) that improves 
cardiac contraction by binding to cardiac myosin and increasing the probability of force 
generating interactions between myosin and actin during the cardiac cycle3, 4. This pharmacology 
has been shown to result in dose-dependent increases in stroke volume in both healthy 
volunteers5 and patients with heart failure6. Given that impaired systolic performance could be a 
major contributor to symptom burden in patients with HFrEF, there is substantial interest in the 
effect of omecamtiv mecarbil on symptoms in patients with HF. The Chronic Oral Study of 
Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF) study was a phase II 
study of omecamtiv mecarbil in chronic HFrEF evaluating its effects on pharmacodynamics, 
cardiac remodeling, natriuretic peptides, and patient-reported outcomes (PROs). The results of 
COSMIC-HF demonstrated dose-dependent improvements in cardiac function, plasma 
concentrations of natriuretic peptides and left ventricular remodeling after 20 weeks of treatment 
with omecamitiv mecarbil compared to placebo 7. Herein we present data describing the effects 
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of omecamtiv mecarbil on the prespecified exploratory endpoint of heart failure symptoms and 
HRQL in the COSMIC-HF study. 
Methods 
Qualified researchers may request data from Amgen clinical studies. Complete details are 
available at the following: https://wwwext.amgen.com/science/clinical-trials/clinical-data-
transparency-practices/clinical-trial-data-sharing-request.  Details of the design and primary 
results of the COSMIC-HF study (clinicaltrials.gov, NCT01786512) have been published7. 
Briefly, this study evaluated the effects 20 weeks of omecamtiv mecarbil in patients with stable 
HF in 448 outpatients with chronic symptomatic HFrEF (NYHA II or III), LVEF ≤40%, and 
elevated natriuretic peptides (N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥ 200 
pg/mL (≥1200 pg/mL if the patient was in atrial fibrillation).  Patients were randomized 1:1:1 to 
placebo, 25 mg of oral omecamtiv mecarbil twice daily (OM 25 mg), or pharmacokinetically-
guided dose titration (OM-PK) (initial 25 mg twice daily dose, increased to 50 mg twice daily 
depending on plasma concentrations after two weeks).  The entry criteria for COSMIC-HF 
mandated clinical stability and optimized background heart failure therapy at the time of study 
entry, making it well suited to assess the effects of omecamtiv mecarbil on HRQL in HFrEF. The 
study was approved by the relevant Institutional Review Boards or Ethics Committees at 
participating sites, and all patients provided written informed consent. 
PRO Measurements 
Participants completed self-administered the Kansas City Cardiomyopathy Questionnaire 
(KCCQ) at baseline, 16 weeks, and 20 weeks. The KCCQ is a 23-item self-administered, 
disease-specific HRQL instrument that has demonstrated good measurement properties in 
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patients with HFrEF8.  The KCCQ is made up of 8 domains evaluating specific aspects of the 
patient experience. The 8 domains include physical limitation, symptom stability, symptom 
frequency, symptom burden, total symptom score, HRQL, self-efficacy, and social limitations. 
The total symptom score (TSS) is a composite of symptom frequency and symptom burden. The 
physical limitations score (PLS) measures specific physical limitations (e.g, dressing, showering, 
etc). The clinical summary score (CSS) is a composite of the TSS and the PLS. The TSS, PLS, 
and CSS were recently qualified by the FDA for use in measuring these concepts in drug 
development 9. Each domain and summary score is scaled from 0 to 100, with higher scores 
indicating better health status.  Based on prior work, 5 points or greater is generally considered a 
minimally clinically meaningful difference in KCCQ scores10. In addition to the KCCQ, patients 
and clinicians also assessed the overall burden of symptoms using the Patient Global Rating of 
Severity (PGR-S) and Clinician Global Rating of Severity (CGR-S), which are 6 point Likert 
scale assessments rating the severity of symptoms from “none” to “very severe.”  In additional 
analyses assessing the effect of baseline symptoms severity on the treatment effect of omecamtiv 
mecarbil, we grouped patients by whether they had rated their baseline symptoms as none, very 
mild, or mild (N = 242) or as moderate, severe, or very severe (N = 202).   
Statistical Analysis 
Descriptive statistics are presented as means (standard deviation), medians (intra-quartile range), 
and percentages, as appropriate. Summary statistics were produced using observed data only 
without applying models or imputation. Participants with missing data were considered non-
responders in categorical responder analyses. P < 0.05 was considered to represent statistical 
significance. There was no adjustment for multiple comparisons.  
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Treatment group differences for changes in TSS, PLS, and CSS were estimated by using 
a repeated measures model (ANOVA) fitted separately for each variable and included the 
stratification factor of presence or absence of atrial fibrillation/flutter at randomization, baseline 
value, treatment group, visit, and the treatment group by visit interaction. An unstructured 
covariance matrix was used to account for the correlation between visits within a subject. 
Pearson correlation coefficients were calculated to measure the correlation of QOL with 
natriuretic peptides and LV dimensions. 
Results 
Baseline characteristics dichotomized by patient reported symptom severity (as assessed by 
PGR-S) are shown in Table 1. In general, patients with less severe symptoms and patients with 
more severe symptoms at baseline were broadly similar, except for KCCQ scores. For placebo, 
OM 25 mg, and OM-PK groups, the median baseline TSS was 70.8 (56.3, 87.5), 74.5 (52.1, 
90.6), and 68.8 (53.1, 85.4), respectively; the median baseline PLS was 62.5 (45.8, 83.3), 66.7 
(50.0, 83.3), and 62.5 (45.8, 85.0), respectively, and the median baseline CSS was 69.2 (52.1, 
82.3), 68.7 (49.9, 85.4), and 67.2 (50.0, 83.3), respectively. These scores are consistent with 
moderate limitation in health status, and represented more symptomatic patients compared to 
those reported in other recent trials in chronic HFrEF (e.g, median CSS was 72 in DAPA-HF and 
76 in PARADIGM-HF). 11, 12   Rates of missingness for KCCQ data were generally low (≤ 20 
missing values for each treatment group and timepoint). 
Effect of Omecamtiv Mecarbil on Symptoms and HRQL 
The overall effects of omecamtiv mecarbil on TSS, PLS, and CSS measured at 16 and 20 weeks 
are shown in Figure 1. For the TSS, the mean change in score from baseline to 20 weeks was 5.0 
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for placebo, 6.6 for OM 25 mg (p = 0.32 vs placebo), and 9.9 for OM-PK (p = 0.03 vs placebo). 
For the PLS, the mean change in score from baseline to 20 weeks was 3.1 for placebo, 6.0 for 
OM 25 mg (p = 0.12 vs placebo), and 4.3 for OM-PK (p = 0.42 vs placebo). For the CSS, the 
mean change in score from baseline to 20 weeks was 4.1 for placebo, 6.3 for OM 25 mg (p = 
0.19 vs placebo), and 7.0 for OM-PK (0.14 vs placebo). As shown in Figure 1, these trends on 
KCCQ were evident by 16 weeks of treatment and persisted to week 20. Given that a 5-point 
change in KCCQ score has been proposed as a minimum clinically important change, we 
assessed the proportion of patients with an improvement of that amount or greater in each group 
for each domain (i.e, “responders”). In this analysis the proportion of responders did not differ 
significantly between placebo and omecamtiv mecarbil for any of the KCCQ scores (Table 2). 
Change in Symptoms and HRQL by Baseline Symptoms Severity 
Since the COSMIC-HF study enrolled patients with a spectrum of symptoms (from minimally to 
highly symptomatic), we performed additional analyses stratifying the population by severity of 
baseline symptoms. The rationale for these analyses was that patients who were more 
symptomatic at baseline had a greater opportunity for improvement than those with milder 
symptoms at baseline. For these analyses, we utilized the baseline Patient Global Rating of 
Severity (PGR-S) score, in which patients rated their symptom burden on a 6-point Likert scale 
from “none” to “very severe”, in order to stratify participants based on their self-reported 
symptom severity. We grouped patients by whether they had rated their symptoms as none, very 
mild, or mild (N = 242) or as moderate, severe, or very severe (N = 202).  In this analysis, the 
improvement in symptoms with omecamtiv mecarbil compared to placebo was greater for those 
with more severe symptoms (Figure 2).  Similarly, the differences in the proportion of 
responders (≥ 5 point improvement in KCCQ score) between omecamtiv mecarbil and placebo 
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were numerically greater in patients with moderate to severe symptoms at baseline, although 
none of these differences were statistically significant.   
Correlation of QOL with Natriuretic Peptides and LV dimensions 
Given that an important objective of the COSMIC-HF study was to assess the impact of 
omecamtiv mecarbil on ventricular remodeling and natriuretic peptides, we assessed the 
relationship between improvements in KCCQ and changes in both ventricular remodeling and 
NT-proBNP observed in COSMIC-HF. As previously reported, treatment with omecamtiv 
mecarbil in COSMIC-HF improved LV remodeling (ventricular volumes and left ventricular 
ejection fraction) and reduced plasma NT-proBNP compared to placebo 7. In the current 
analysis, there was a modest relationship between improvements in KCCQ and decrease in NT-
proBNP for PLS (r = -0.08, p = 0.098), CSS (r = -0.14, p = 0.007), and TSS (r = -0.15, p = 
0.002). These relationships were strongest for patients assigned to the PK-titration arm; PLS (r= 
-0.15, p = 0.093), CSS (r = -0.23 p = 0.009), and TSS (r = -0.26, p = 0.003). There was no
significant relationship between changes in LV remodeling and changes in KCCQ scores (data 
not shown).  
Discussion 
Improvement in patient reported outcomes is an important goal in the management of heart 
failure. In the current analysis, administration of omecamtiv mecarbil improved HRQL as 
measured by the TSS compared to placebo. Other domains of the KCCQ were not significantly 
different.  This analysis focused on those domains of the KCCQ, specifically the TSS, PLS, and 
CSS, that have recently been qualified by the FDA for assessing the benefits of interventions for 
heart failure.  As might be anticipated, observed changes were greatest in patients who were 
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most symptomatic at baseline, whereas the changes in KCCQ in patients with no or minimal 
symptoms at baseline were negligible.  
These data should be compared to reports of the effects of other interventions for HFrEF 
on KCCQ scores. In general, effective heart failure therapies have a variable effect on HRQL. 
For older therapies such as beta-blockers and ACE-inhibitors, there are few data directly 
assessing HRQL compared to placebo and none using the KCCQ. Beta-blockers have notable 
effects on ventricular remodeling, morbidity and mortality but appear to exert little or no effect 
on improving HFQoL13.  More recently developed therapies for HFrEF had undergone more 
rigorous assessment of their effect on HRQL. The largest reported effects are in the 2-3 point 
improvement in KCCQ range, specifically for dapagliflozin 11, or exercise training 14. The 
CARE-HF study of cardiac resynchronization therapy showed a more marked improvement on 
HRQL but used the Minnesota Living with Heart Failure score15, as did the AHEFT study of 
nitrates and hydralazine in self-identified black patients16.  Notably, the angiotensin-receptor 
blocker/neprilysin-inhibitor sacubitril-valsartan improved the CSS by a more modest mean 
change of 0.9 points after 8 months of treatment compared to enalapril 12, despite the large 
observed differences in morbidity and mortality between the two treatment arms 17. In this 
context, the improvements seen in HRQL for the OM-PK titration group over placebo at 20 
weeks of treatment by TSS (4.9 points) equals or exceed those of common effective heart failure 
therapies. These improvements are numerically greater when limited to the subgroup of patients 
who were more symptomatic at baseline (6.5 for TSS).  
The specific mechanisms underlying the improvements in QOL with effective HF 
therapies are poorly defined and probably diverse. Given the mechanism of action of omecamtiv 
mecarbil is to improve left ventricular performance, we analyzed whether improvement in 
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symptoms and HRQL might mirror changes in LV remodeling and/or natriuretic peptides, both 
of which were improved by omecamtiv mecarbil treatment compared to placebo in COSMIC. 
However, we found only modest relationships between improvements in KCCQ scores and 
declines in plasma NT-proBNP, and none with changes in ventricular function or remodeling. 
These results underscore the complex nature of symptom and HRQL improvement in HF.   
Limitations 
COSMIC-HF was a Phase 2 trial and was not powered to provide definitive evidence of 
beneficial effects on symptoms or HRQL for omecamtiv mecarbil. Given the smaller sample size 
and shorter duration of treatment (20 weeks), and the violation of normality (changes from the 
baseline of PLS), the confidence intervals around the effect estimates on HRQL are broad in 
comparison to those from larger phase 3 studies of other therapies, and most of the observed 
differences in KCCQ did not reach statistical significance. It is possible that our results are 
related to the play of chance rather than a true treatment effect. Given the sample size of 
COSMIC-HF and the modest number of clinical events, we are not able to assess the relationship 
between the observed KCCQ improvements and clinical outcomes.  
Conclusions 
In COSMIC-HF, randomization to omecamtiv mecarbil led to = statistically significant 
improvement in TSS in the OM-PK titration group compared to placebo. Point-estimates of the 
effect of KCCQ were of a similar or greater magnitude to those seen with other effective 
pharmacological interventions for heart failure.  The effect of omecamtiv mecarbil on heart 
failure symptoms, specifically the TSS of the KCCQ, is being further tested prospectively as a 
pre-defined secondary endpoint, in ongoing trials focused on morbidity and mortality 
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(GALACTIC-HF, NCT NCT02929329)18and exercise capacity (METEORIC-HF, NCT 
NCT03759392) which will further inform the clinical benefits of this potential therapy in 
patients with HFrEF. 
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Table 1. Baseline Characteristics Stratified by Symptom Severity 
PGR-S: None, very mild or mild symptoms PGR-S: Moderate, severe, or very severe 
symptoms 
Placebo 
(n = 81) 
Omecamtiv 
Mecarbil 
25 mg BID 
(n = 86) 
Omecamtiv 
Mecarbil  
PK-Titration 
Group 
(n = 75) 
Placebo 
(n = 67) 
Omecamtiv 
Mecarbil 
25 mg BID 
(n = 64) 
Omecamtiv 
Mecarbil  
PK-Titration 
Group 
(n = 71) 
Age, years 64.0 ± 9.8 63.5 ± 9.9 63.0 ± 10.4 63.2 ± 9.8 61.8 ± 10.6 62.6 ± 13.0 
Men, no. (%) 65 (80.2) 74 (86.0) 63 (84.0) 54 (80.6) 53 (82.8) 59 (83.1) 
White Race, no. (%) 73 (90.1) 81 (94.2) 70 (93.3) 62 (92.5) 61 (95.3) 68 (95.8) 
Systolic blood pressure, mmHg 119.7 ± 15.0 121.4 ± 17.1 120.6 ± 16.3 118.9 ± 14.1 120.0 ± 15.3 116.2 ± 15.6 
Heart rate, bpm 69.3 ± 10.4 68.6 ± 11.5 69.6 ± 10.8 70.4 ± 10.1 70.2 ± 10.6 71.3 ± 11.5 
Ejection Fraction, % 30.1 ± 7.0 30.2 ± 7.0 28.9 ± 7.2 28.4 ± 7.9 28.1 ± 8.0 28.8 ± 7.4 
HF characteristics 
Ischemic heart disease, no. (%) 47 (58.0) 56 (65.1) 50 (66.7) 42 (62.7) 41 (64.1) 50 (70.4) 
Years from HF Diagnosis 8.5 ± 7.0 8.8 ± 8.6 7.3 ± 6.5 7.4 ± 7.2 6.2 ± 6.6 8.2 ± 6.5 
Hospitalized for HF in past 12 
months, no. (%) 
22 (27.2) 24 (27.9) 17 (22.7) 16 (23.9) 27 (42.2) 20 (28.2) 
Co-morbidities 
History of: 
Persistent A Fib/Flutter, no. (%) 16 (19.8) 13 (15.1) 11 (14.7) 17 (25.4) 15 (23.4) 12 (16.9) 
Diabetes mellitus, no. (%) 33 (40.7) 44 (51.2) 32 (42.7) 28 (41.8) 26 (40.6) 23 (32.4) 
Hypertension, no. (%) 59 (72.8) 56 (65.1) 53 (70.7) 51 (76.1) 39 (60.9) 45 (63.4) 
Laboratory variables a 
Troponin I, ng/mL, 
median (Q1, Q3) 
0.024 (0.016, 
0.039) 
0.023 (0.016, 
0.042) 
0.019 (0.016, 
0.041) 
0.028 (0.016, 
0.042) 
0.021 (0.016, 
0.035) 
0.024 (0.016, 
0.042) 
NT-proBNP, pg/mL, 
median (Q1, Q3) 
1377.0 (690.7, 
2837.0) 
1398.4 (634.0, 
2962.0) 
1550.9 (699.0, 
3165.0) 
1942.4 (915.0, 
3373.1) 
1644.2 (628.4, 
3754.9) 
1847.6 (983.1, 
3151.0) 
eGFR,  mL/min/1.73m2 62.95 ± 17.82 63.07 ± 19.76 65.21 ± 18.93 66.96 ± 20.72 63.42 ± 17.51 64.66 ± 18.64 
Heart Failure Therapies, no. (%) 
ACE inhibitor and/or ARB 77 (95.1) 81 (94.2) 67 (89.3) 62 (92.5) 61 (95.3) 68 (95.8) 
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Beta-blockers 80 (98.8) 83 (96.5) 72 (96.0) 65 (97.0) 63 (98.4) 70 (98.6) 
MRAs 46 (56.8) 44 (51.2) 47 (62.7) 41 (61.2) 43 (67.2) 46 (64.8) 
Diuretics other than MRAs 65 (80.2) 72 (83.7) 67 (89.3) 59 (88.1) 56 (87.5) 65 (91.5) 
Implantable cardiac defibrillator 
(ICD) only 
30 (37.0) 40 (46.5) 32 (42.7) 22 (32.8) 18 (28.1) 28 (39.4) 
Cardiac resynchronization 
therapy (CRT) without ICD 
3 (3.7) 2 (2.3) 1 (1.3) 2 (3.0) 0 (0.0) 0 (0.0) 
Cardiac resynchronization 
therapy (CRT) with ICD 
22 (27.2) 20 (23.3) 18 (24.0) 8 (11.9) 19 (29.7) 19 (26.8) 
KCCQ (median, IQR) 
PLS 75.0 (58.3, 87.6) 75.0 (60.0, 91.7) 79.2 (62.5, 91.7) 50.0 (37.5, 70.8) 50. 0 (33.3, 62.5) 50.0 (37.5, 62.5) 
TSS 81.3 (64.6, 89.6) 84.9 (68.8, 93.8) 81.3 (66.7, 91.7) 60.4 (44.8, 76.0) 54.2 (53.3, 63.4) 55.2 (40.6, 70.8) 
CSS 76.6 (62.5, 87.0) 81.0 (65.6, 91.7) 77.0 ± 16.3 52.6 (41.2, 69.8) 50.8 (41.7, 67.5) 50.0 (40.6, 67.7) 
Note: Mean ± SD, unless otherwise noted. a Laboratory variables, heart failure therapies and echocardiographic variables excludes 3 patients who were 
randomized but not dosed. PGR-S = Patient Global Rating of Severity. TSS = total summary score, PLS = physical limitations score, CSS = clinical summary 
score. HF = heart failure. ARB = angiotensin receptor blocker. MRA = mineralocorticoid receptor antagonist. ICD = implantable cardiac defibrillator. CRT = 
cardiac resynchronization therapy * p <0.05, all others p > 0.05; P-values provided as a measure of baseline difference and not for statistical testing. Continuous 
variable p-values are from ANOVA tests and categorical variable p-values from chi-square tests.  
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Table 2. Proportion of Patients with Minimally Clinically Important Difference in KCCQ Scores by Treatment, Stratified by 
Baseline Symptom Severity 
Placebo 
(n = 149) 
Omecamtiv 
Mecarbil 
25 mg BID 
(n = 150) 
P value vs. 
placebo 
Omecamtiv 
Mecarbil  
PK-Titration 
Group 
(n = 146) 
P value vs. 
Placebo 
PLS (N, %) 54 (36%) 70 (47%) 0.09 60 (41%) 0.46 
PLS—mild symptoms (N, %) 26 (32%) 34 (40%) 0.40 27 (36%) 0.73 
PLS- mod-severe symptoms (N, %) 28 (42%) 36 (56%) 0.14 33 (47%) 0.70 
TSS (N, %) 68 (46%) 68 (45%) 1.00 70 (48%) 0.78 
TSS—mild symptoms (N, %) 34 (42%) 31 (36%) 0.53 29 (39%) 0.80 
TSS- mod-severe symptoms (N, %) 34 (51%) 37 (58%) 0.52 41 (58%) 0.51 
CSS (N, %) 61 (41%) 69 (46%) 0.44 66 (45%) 0.53 
CSS—mild symptoms (N, %) 32 (40%) 32 (37%) 0.88 25 (33%) 0.53 
CSS- mod-severe symptoms (N, %) 29 (43%) 37 (58%) 0.14 41 (58%) 0.13 
TSS = total summary score, PLS = physical limitations score, CSS = clinical summary score. 
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Figure Legends 
Figure 1. Mean change in KCCQ from baseline through week 16 and 20 for Total Symptom 
Score (TSS), Physical Limitations Score (PLS), and Clinical Summary Score (CSS). Error bars 
show +/-standard error. * = p ≤ 0.05, all other comparisons p > 0.05. 
Figure 2. Change in Total Symptom Score (TSS), Physical Limitations Score (PLS), and 
Clinical Summary Score (CSS) based on Symptom Severity at Baseline.  
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